Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Expression of Immune Checkpoint Markers PD-1, PD-L1, CD8, MSI, and p53 in Advanced Serous Ovarian Carcinoma

Ana Paula Dergham
* ORCID logo ,
Seigo Nagashima
ORCID logo ,
Caroline Busatta Vaz de Paula
ORCID logo ,
Marcia Olandoski
,
Lucia De Noronha
,
Vanessa Santos Sotomaior
Version 1 : Received: 2 May 2023 / Approved: 4 May 2023 / Online: 4 May 2023 (03:39:48 CEST)

A peer-reviewed article of this Preprint also exists.

Dergham, A.P.; Vaz de Paula, C.B.; Nagashima, S.; Olandoski, M.; de Noronha, L.; Sotomaior, V.S. Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study. J. Pers. Med. 2023, 13, 1045. Dergham, A.P.; Vaz de Paula, C.B.; Nagashima, S.; Olandoski, M.; de Noronha, L.; Sotomaior, V.S. Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study. J. Pers. Med. 2023, 13, 1045.

Abstract

Abstract: Advanced high-grade serous ovarian carcinoma is a serious malignant neoplasm with a late diagnosis and high mortality rate. Even when treated with standard therapy, such as surgery followed by carboplatin and paclitaxel chemotherapy, the prognosis remains unfavorable. Im-munotherapy is a treatment alternative that requires further study. Therefore, we aimed to evaluate the expression of the immunotherapy markers: PD-1, PD-L1, CD8, MSI (MLH1, MSH2, MSH6, and PMS2), and p53 in the paraffin samples of high-grade serous ovarian carcinoma. A retrospective study of 28 southern Brazilian patients with advanced serous ovarian carcinoma (EC III or IV) was conducted between 2009 and 2020. The expression of these proteins was evaluated using im-munohistochemistry, and the results were correlated with the patients' clinicopathological data. At diagnosis, the mean age was 61 years, and the most common clinical stage (60%) was EC III. Among the cases, 84.6% exhibited p53 overexpression, 14.8% had MSI, 92.0% were sensitive to platinum, and more than 50.0% relapsed after treatment. Patients with MSI had a lower CD8/PD-1 ratio and more relapses (p=0.03). In conclusion, analysis of immunotherapeutic markers in paraf-fin-embedded samples of advanced serous ovarian carcinoma is feasible and may assist in prog-nosis.

Keywords

biomarkers; immunotherapy markers; advanced serous ovarian carcinoma; immunohistochemistry; p53; MSI

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.